Application of database of International Cancer Genome Consortium
Hao Hua
Wang Xindi
Geng Hui
Yuan Wei
Chen Xinhuan
Wang Jun
Ma Mao
Abstract：With the vigorous development of molecular biology technology in the 21st century,high-throughput sequencing technology has identified a large number of cancer mutation genes and molecular markers.Facing the interaction of huge orders of magnitude genes,various non-coding RNAs and their complex regulatory functions,modern medicine has revealed the potential mode of action and the development process of cancer from a molecular perspective.It is difficult to accurately explain the molecular mechanism of target cancer,so it is urgent to combine the information data of high throughput gene expression,epigenomics,proteomics,transcriptomics,to conduct molecular genetics,molecular pharmacology and etiology and pathology analyses for obtaining potential cancer risk,typing,etc,to identify oncogenes for somatic mutation sites,base changes,functional influence and other levels of data,and to deeply reveal the occurrence and development of cancer,drug targets,prognosis and cancer subtypes for treatment,etc.In order to solve the above problems,the International Cancer Genome Consortium(ICGC)collects cancers from 50 different cancer types or subtypes to establish a database that facilitates researchers to conduct large-scale cancer gene level research.The systematic research is conducted on more than 25,000 cancer genomes at the levels of genomics,epigenomics and transcriptomics for analyzing possible effects of oncogenic mutant genes and mutagenesis.The purpose is to determine clinically relevant subtypes for cancer prognosis and treatment management,and promote development of new cancer drug therapies.
Keywords：CancerInternational Cancer Genome ConsortiumGene mutationsClinical relevant subtypes
Publication Date：2024-02-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 144-148 )